AI ECG Screening: Unlocking Structural Heart Disease Value

We’re missing far too many cases of asymptomatic structural heart disease. Patients walk around with ticking time bombs in their chests, and because they feel fine, they don’t get diagnosed until it’s too late, leading to poor outcomes. This piece lays out a clinical challenge and shows how AI-enabled electrocardiogram (ECG) algorithms can be plugged into primary care and cardiology screening to catch these silent conditions. It all comes down to a practical question: when an AI-ECG signal hits your inbox, what’s the protocol for ordering an echo, especially when screening for low ejection fraction?

The Imperative of Early Detection: Asymptomatic Left Ventricular Dysfunction

Finding asymptomatic left ventricular dysfunction (ALVD), basically, a low ejection fraction in someone with no overt heart failure symptoms, gives us a chance to intervene. We can get these patients on guideline-directed medical therapy, which can seriously alter their disease course and even head off symptomatic heart failure entirely. But we can’t just give everyone an echocardiogram. It’s impractical and way too expensive. This leaves a massive gap in our screening capabilities, which is where a cheap, easy-to-use tool that can be deployed across an entire health system comes in. A standard ECG is everywhere, but its sensitivity for ALVD is pretty weak on its own. AI gets around this by spotting subtle patterns in a standard 12-lead ECG that a human simply can’t see, which drastically improves the diagnostic yield from a test we’re already doing. The FDA is trying to keep up, creating specific pathways like the Breakthrough Device Designation program to get these tools into clinics faster. Cardiology has seen a huge number of these designations, making up a big chunk of the over 1,300 total designations granted to date and showing just how fast this field is moving FDA Breakthrough Device program cardiology statistics.

Clinical Validation: Mayo Clinic’s AI-ECG Algorithm and Real-World Evidence

For any AI to be clinically useful, it can’t just be a black box. It has to be built on a massive set of real patient data and have its results validated in peer-reviewed outcome studies. The Mayo Clinic’s AI-ECG algorithm for detecting low ejection fraction is a perfect example. It was built on an enormous private dataset that paired ECGs with actual echo results, which is the kind of “data moat” you need to build a top-tier algorithm. Anumana, a company that spun out of Mayo, took that technology and turned it into a commercial product, showing how this stuff can actually move from an academic center to the bedside. The evidence comes from clinical trials in primary care settings. One of the big peer-reviewed studies showed the AI-ECG could pick out patients with ALVD with high sensitivity and specificity. Critically, the trial included patients from all sorts of backgrounds, so we have some confidence the findings aren’t just limited to one demographic group. They didn’t just look at the AI in a vacuum. They benchmarked its performance against the standard diagnostic methods we use today, confirming its utility as a screening tool that can accurately identify asymptomatic left ventricular dysfunction (defined as an ejection fraction below 50% in patients without a prior heart failure diagnosis). RCTs are the gold standard, sure, but real-world evidence (RWE) from electronic health records, registries, and claims data gives us a much better picture of how these algorithms actually work in the chaos of day-to-day clinical practice. This ongoing data is how you spot things like algorithmic drift, where an algorithm’s performance degrades as patient populations change over time, a major concern with any learning system.

FDA Pathways and Peer-Review Standards for AI-Enabled ECGs

You can’t just drop a new AI tool into a clinic. Getting it through the FDA regulatory process is the only way to ensure it’s safe and to avoid massive liability. Most of these cardiac AI tools are classified as Software as a Medical Device (SaMD), and the usual route to market is a 510(k) clearance, which involves showing it’s substantially equivalent to a device that’s already out there. But if your AI does something totally new, like predict a rare arrhythmia years in advance, you’ll probably need a De Novo classification request. For an AI-ECG algorithm, it’s absolutely essential to be able to make updates, like retraining on new data, without going back to the FDA for a full review every single time. A Predetermined Change Control Plan (PCCP) lets you do exactly that by getting the FDA to pre-approve your process for making specific types of updates. This means you can refine the model based on real-world performance data, keeping it sharp without getting bogged down in regulatory paperwork for every little tweak. Without a PCCP, is the idea of an “adaptive” AI that learns over time even possible? It’s basically a non-starter from a regulatory standpoint. And the standards don’t stop at launch. Ongoing post-market surveillance, real-world performance monitoring, and adherence to Good Machine Learning Practice (GMLP) are required to catch problems. GMLP is the set of 10 guiding principles from the FDA, Health Canada, and MHRA. These principles aren’t just suggestions. They are the ground rules for everything from how you handle data to how you monitor for bias, which is the only way to build an AI that clinicians can actually trust.

A Diagnostic Protocol for AI-ECG Flagged Patients

So you’ve got this tool. Now what? For both cardiologists and PCPs, the biggest question is what to do when the AI flags a patient. The AI is there to augment your judgment, acting as a “wedge product” to surface the high-risk patients you might otherwise have missed. Imagine a patient comes into their PCP’s office for a routine check-up. You run a standard 12-lead ECG, which then gets analyzed by an FDA-cleared AI algorithm for low ejection fraction.

• Scenario 1: AI-ECG Negative. If the algorithm says there’s a low probability of ALVD, the patient just continues with routine care. You’re done. No need for immediate cardiac imaging based on this screen.
• Scenario 2: AI-ECG Positive. If the algorithm flags the ECG as positive for potential low ejection fraction, that’s your trigger. The PCP should then refer the patient for a formal echocardiogram. This referral is a critical step. Think of the AI-ECG as a sensitive filter, not the final word.
• Echocardiogram Confirmation: The echo gives you the definitive answer on the left ventricular ejection fraction. If it confirms ALVD, you can get the patient started on guideline-directed medical therapy and refer them to cardiology.
• Echocardiogram Negative: If the echo comes back negative even though the AI flagged it, that’s okay. It just means you found a false positive. Even a false positive from the AI provides useful information, you’ve now confidently ruled out a serious heart condition with an echo, which is a lot better than just wondering and potentially delaying a diagnosis down the road. Following a rigid protocol like this is how you use AI responsibly. It keeps the physician in the loop and relies on definitive tests like an echo for the actual diagnosis. This is just good Clinical Decision Support (CDS) in practice, the AI makes a recommendation, the human makes the call.
  

  Oversight and Continuous Improvement

  Long-term, these tools are only as good as their oversight. That means having systems in place to monitor real-world model performance, audit data inputs, and build in feedback loops so clinicians can flag weird results. The companies building these tools also have to live up to tough security and privacy standards like HIPAA, HITRUST, and SOC 2 to protect patient data. That’s just table stakes. Plus, you have to think about getting paid. Widespread adoption won’t happen if there’s no reimbursement path. Getting CPT (Current Procedural Terminology) codes, especially the Category III codes for emerging tech, is a huge step. It signals that these technologies are being integrated into clinical practice and gives providers a way to bill for using them. Anumana, for example, already secured CPT codes for its AI-ECG algorithms, which helps clear the path for others Anumana CPT code information. Using AI-ECG screening for asymptomatic structural heart disease is a big step forward for preventive cardiology. By sticking to rigorous FDA pathways, demanding peer-reviewed outcome validation, setting up clear clinical guardrails, and having strong oversight, these tools can actually change how we do early detection and improve patient lives. The partnership between groups like Mayo Clinic and Anumana shows how you can take a great idea and, by holding it to high clinical and regulatory standards, bring a reliable AI tool to the clinic.